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Background. The long-term eﬃcacy of aldosterone-receptor antagonists (ARAs) as add-on treatment in uncontrolled hypertension
has not yet been reported. Methods. Data from 123 patients (21 with primary aldosteronism, 102 with essential hypertension) with
diﬃcult-to-treat hypertension who received an ARA between May 2005 and September 2009 were analyzed retrospectively for
their blood pressure (BP) and biochemical response at first followup after start with ARA and the last follow-up available. Results.
Systolic BP decreased by 22± 20 and diastolic BP by 9.4± 12mmHg after a median treatment duration of 25 months. In patients
that received treatment >5 years, SBP was 33 ± 20 and DBP was 16 ± 13mmHg lower than at baseline. Multivariate analysis
revealed that baseline BP and follow-up duration were positively correlated with BP response. Conclusion. Add-on ARA treatment
in diﬃcult-to-treat hypertension results in a profound and sustained BP reduction.
1. Introduction
Aldosterone-receptor antagonists (ARAs) have been shown
to be eﬀective in blood pressure (BP) reduction [1–
11], but until recently their use was mainly limited to
certain conditions such as liver cirrhosis, heart failure,
and primary aldosteronism (PA). With the recognition of
PA as a common cause of resistant hypertension [12], a
renewed interest in the use of ARAs in hypertension has
emerged. However, aldosterone has also shown to be an
important factor in other forms of resistant hypertension.
In patients with elevated aldosterone-to-renin ratios (ARRs)
and plasma aldosterone levels, but without genuine PA
based on suppression testing, BP control was harder to
achieve than in essential hypertensives (EHs) [13]. Further-
more, a proportion of patients treated with angiotensin-
converting enzyme inhibitors (ACE-Is) or angiotensin recep-
tor blockers (ARBs) show aldosterone breakthrough [14–16],
contributing to therapy resistance by partly counteracting
the intended blockade of the renin-angiotensin-aldosteron-
system (RAAS).
The use of ARAs in resistant hypertension, therefore,
seems rational, and several publications have pointed out
the potential of aldosterone blockade in diﬃcult-to-treat or
resistant hypertension [17–24]. In many of these studies, the
addition of spironolactone resulted in an impressive drop
in systolic BP (SBP) of up to 25mmHg and 12 mmHg in
diastolic BP (DBP). However, most of these studies were
either open label [17, 18, 20, 22], or retrospective [19, 21,
23] in design. One randomized, placebo-controlled, double-
blind trial was performed comparing spironolactone with
amiloride, the combination of both drugs, and placebo in
black hypertensive patients with uncontrolled hypertension
despite treatment with at least a diuretic and a calcium-
channel-blocker [24]. Interestingly, the BP response was
considerably smaller than in the aforementioned studies
(−7.3 in SBP and −3.3mmHg in DBP for spironolactone
versus placebo). De Souza et al. recently performed an
open-label, prospective study on the BP-lowering benefits
of spironolactone in patients with resistant hypertension.
By using 24-hour ambulatory BP measurements, at least
part of the potential white coat and placebo eﬀect could be
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accounted for. Twenty-four-hour SBP and DBP decreased
by 16 and 9 mmHg, respectively, after a median treatment
duration of 7 months, and in a subgroup, the persistence of
this eﬀect was confirmed up to 15 months [22]. So far, longer
followup periods have not been reported and although a
persistence of the eﬀect in the long run is expected, this
remains to be confirmed.
Predicting factors for the BP response to ARA treatment
have been identified in several studies. Lower serum potas-
sium levels were pointed out by several groups to be associ-
ated with a larger decrease in BP [19, 21, 22, 25]. Most studies
found no relation between plasma renin concentration or
activity and the BP lowering response to ARAs [5, 9, 17, 26].
Also neither plasma aldosterone levels nor ARR levels seem
to predict the BP-lowering eﬀect [22, 26], although this could
have been caused by the interfering eﬀects of multidrug
antihypertensive regimens on the ARR in these patients [25].
Other factors possibly associated with a better response are
the absence of diabetes [23], higher waist circumference,
lower aortic pulse wave velocity [22], and a lower baseline
high-density lipoprotein (HDL) cholesterol [21].
ARAs have been prescribed in our clinic to patients with
diﬃcult-to-treat hypertension for a long time now, often
with good results even after many years. This study aims to
retrospectively characterize the long-term response to ARA
treatment in patients with diﬃcult-to-treat hypertension and
to identify factors associated with this response.
2. Methods
2.1. Patients. All patients who visited the outpatient hyper-
tension clinic of the Erasmus Medical Center in Rotterdam
and the TweeSteden Hospital in Waalwijk, the Netherlands,
between May 2005 and September 2009 were screened for
their eligibility for the study. Patients were selected when
they had uncontrolled hypertension (BP > 140/90mmHg,
or >130/80mmHg for patients with diabetes mellitus (DM)
or manifest cardiovascular disease) despite the use of at least
two antihypertensive drugs and were put on spironolactone
or eplerenone during the study period. Patients who were
already using an ARA when referred to our clinic were
excluded. Patients of whom insuﬃcient data was available
to meet the primary objective (for instance insuﬃcient data
on medication use or the absence of a BP measurement at
the start of treatment or last followup) or patients who were
prescribed an ARA for another indication than hypertension
were also excluded from the analysis.
2.2. Clinical Data. At baseline, patients’ sex, height, weight,
the time of diagnosis of hypertension, their antihypertensive
medication, their family history, and the presence or absence
of diabetes at the start of ARA treatment were collected
from patient files. Their electrocardiograms (ECGs), when
not taken longer than one year before start of treatment,
were scored for the presence of left ventricular hypertrophy
(LVH) according to the Sokolow-Lyon criteria. The presence
or absence of PA was based on the clinical judgement by their
physician.
At baseline, at first followup (i.e., the first followup visit
that BP was measured after start of ARA treatment), and
at the end of followup (i.e., the date that ARA treatment
was permanently discontinued or the last visit before the
end of data collection), the following parameters were
recorded: BP, serum sodium, potassium, urea, creatinine,
uric acid, glucose, total cholesterol, high-density lipoprotein
(HDL), low-density lipoprotein (LDL), and hemoglobin and
hematocrit, and plasma renin and aldosterone levels, where
available.
BP measurements were taken in triplicate at an interval
of five minutes with a semiautomatic BP measuring device
after a rest of five minutes in sitting position. The mean of
these measurements was used in the analysis.
Biochemical measurements were taken on the visit day or
the nearest previous moment.
Plasma renin concentrations (PRCs) were assessed using
an immunoradiometric assay (Renin III, Cisbio, Gif-sur-
Yvette, France). Plasma aldosterone concentrations (PACs)
were measured with a radioimmunoassay (Coat-a Count,
Diagnostics Product Corporation, LA, CA, USA). Hyper-
kalemia was defined as serum potassium levels exceeding
5.5mmol/L.
2.3. Data Analysis. Statistical analyses were performed in
SPSS 17.0 for Windows.
Main eﬀects at first followup and end of followup were
calculated. Furthermore, to assess the long-term eﬃcacy of
treatment, patients were stratified based on the duration of
followup into the following categories: <1 year, 1–5 years,
and >5 years followup.
Values are expressed as mean ± SD, or as median
and range when not normally distributed. Medication use
was quantified by adding up the total number of diﬀerent
drugs, as well as by assessing the defined daily doses
(DDDs) per drug and for total drug use according to the
World Health Organization Anatomical Therapeutic Chemi-
cal (ATC) index [27]. Diﬀerences within subjects were tested
using paired Student’s t-tests for two groups and one-way
analysis of variance (ANOVA) for repeatedmeasurements for
more groups. Between-subjects diﬀerences were tested with
unpaired t-tests for two groups and one-way ANOVA for
more groups. For values that were abnormally distributed,
nonparametric tests were used (Mann-Whitney U test and
Wilcoxon Signed Ranks test). Diﬀerences in proportions
were tested with a chi-square test.
Patients with PA were excluded for regression analysis. A
univariate linear regression analysis was performed to iden-
tify potential determinants of the BP response. Significant
parameters were subsequently tested in a multivariate linear
regression analysis. This model was further adjusted for age
and sex.
3. Results
3.1. Study Population. A total of 175 patients were prescribed
an ARA during the study period. Fifty-two patients were
excluded: 39 because of insuﬃcient data, 5 because our
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Table 1: Baseline characteristics of the study population.
Total EH PA P-value
Number 123 102 21
Age (years) 56.6 ± 10.7 56.7 ± 11.2 56.5 ± 8.2 .959
Male (%) 60.1 56.9 76.2 .099
BMI (kg/m2) 29.4 ± 5.0 29.3 ± 5.0 30.1 ± 5.2 .537
SBP (mmHg) 159.7 ± 19.1 158.4 ± 18.3 166.0 ± 21.7 .094
DBP (mmHg) 93.3 ± 12.2 92.7 ± 12.5 96.0 ± 10.8 .268
Time since diagnosis (years) 10.0 (0–50) 10.0 (0–50) 7.5 (1.0–34) .319
Age at diagnosis (years) 42.0 ± 13.0 41.5 ± 13.3 44.7 ± 11.4 .335
Nr. of antihypertensives 3 (2–6) 3 (2–6) 3 (2–5) .071
DDD 5.0 (1.25–13.0) 5.0 (1.25–13.0) 3.7 (1.5–10.0) .117
DM (%) 22.8 23.2 21.1 .842
LVH (%) 28.5 26.5 38.1 .125
Family history of HT 52.0 53.9 42.9 .355
Serum sodium (mmol/L) 141.5 ± 2.7 141.2 ± 2.8 143.0 ± 2.14 .008
Serum potassium (mmol/L) 3.9 ± 0.6 4.0 ± 0.6 3.4 ± 0.5 <.001
Serum creatinine (μmol/L) 83.8 ± 20.1 83.8 ± 21.1 84.1 ± 14.4 .959
Serum uric acid (mmol/L) 0.36 ± 0.08 0.37 ± 0.08 0.34 ± 0.08 .134
Hemoglobin (mmol/L) 8.9 ± 0.82 8.8 ± 0.8 9.5 ± 0.6 .001
Hematocrit (%) 0.42 ± 0.04 41.3 ± 3.6 45.3 ± 2.1 .003
Cholesterol (mmol/L) 5.31 ± 0.96 5.27 ± 0.97 5.55 ± 0.90 .345
HDL (mmol/L) 1.35 ± 0.42 1.37 ± 0.41 1.26 ± 0.44 .347
LDL (mmol/L) 3.37 ± 1.02 3.41 ± 1.02 3.16 ± 1.03 .407
Glucose (mmol/L) 5.5 ± 1.6 5.5 ± 1.6 5.5 ± 1.8 .943
ACR (g/mol) 2.19 (0.95–12.4) 2.19 (0.15–453.8) 1.96 (0.37–592.0) .518
PAC (pmol/L) 282.5 (2.8–4172) 224.4 (2.8–4172) 548.5 (199–2282) P < .001
PRC (mU/L) 13.9 (1.0–4374) 19.8 (1.0–4374) 5.8 (1.8–18.9) P < .001
ARR (pmol/mU) 19.4 (0.3–1087) 9.5 (0.3–781) 82.7 (17.4–1087) P < .001
(EH: essential hypertension; PA: primary aldosteronism; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; DDD: defined
daily dose; DM: diabetes mellitus; LVH: left ventricular hypertrophy; HT: hypertension; HDL: high-density lipoprotein; LDL: low-density lipoprotein; ACR:
urinary albumin-to-creatinine ratio; PAC: plasma aldosterone concentration; PRC: plasma renin concentration; ARR: aldosterone-to-renin ratio).
criteria for diﬃcult-to-treat hypertension were not met, 3
because of questionable treatment adherence, 2 because of
a followup duration less than a month, 1 because baseline
BP measurement was not performed with a semi-automatic
BP measuring device, and 1 because an ARA was prescribed
because of another indication than hypertension. In total,
123 patients were included in the analysis with a mean
age of 56.6 ± 10.7 years. The median duration between
diagnosis and start of ARA treatment was 10 years (range 0–
50 years). The median number of diﬀerent antihypertensive
agents was 3 (total DDD 5.0). Twenty-three percent of
patients had DM, and 29 percent had LVH. Twenty-one
patients were diagnosed as having PA by their physician. The
baseline characteristics of all patients and of the EH and
PA subgroups are shown in Table 1. Serum potassium levels
were lower in patients with PA than with EH (3.4mmol/L
versus 4.0mmol/L in EH, P < .001). Serum sodium levels
were higher in patients with PA than with EH (143 versus
141mmol/L, P < .001).
As expected, PRC was lower in PA than in EH patients
(5.8 versus 19.8mU/L, P < .001). PAC and ARR were higher
in PA patients (548.5 versus 224.4 pmol/L (P < .001) for PAC,
and 82.7 versus 9.5 pmol/mU (P < .001) for ARR).
Values of haemoglobin and hematocrit were also higher
in PA than in EH patients.
3.2. Treatment. Ninety-four patients started on spironolac-
tone treatment with a median dose of 50mg daily (range
12.5–100mg). Twenty-nine patients started on eplerenone
with amedian dose of 50mg (range 25–50mg). Total starting
DDD of ARA was 0.67 (range 0.17–1.33). At the end of
followup 91 patients were on spironolactone with a median
dose of 25mg (range 12.5–100mg) and 32 patients on
eplerenone (median dose 50mg, range 25–100mg). Median
ARA DDD at end of followup was 0.67 (range 0.17–2.00).
Median treatment duration at first followup was 8 weeks
(range 1–66 weeks). The median treatment duration at end
of followup was 25 months (range 1–144 months).
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Figure 1: Systolic (SBP) and diastolic (DBP) blood pressure before start with an aldosterone-receptor antagonist (baseline), at first followup
(FU), and at the end of FU in patients with essential hypertension (EH) and primary aldosteronism (PA). Overall trend was tested with
one-way ANOVA for repeated measurements (P < .001 for all groups, except for DBP in the PA group (P = .001)). Indicated significance
levels are for diﬀerences between groups after adjustment for multiple comparisons (∗compared to baseline; #compared to first FU).
Table 2: Changes in biochemical parameters at first followup and end of followup after start of treatment with an aldosterone-receptor
antagonist for patients with essential hypertension (EH) and primary aldosteronism (PA). (Values were tested with one-way ANOVA for
repeatedmeasurements. Indicated P values are for diﬀerences between baseline and first followup (a), first and last followup (b), and baseline
and last followup (c) after Bonferroni adjustment; n represents the number of patients with measurements at all three time points).
n Baseline P valuea First FU P valueb End of FU P valuec
EH
Serum sodium (mmol/L) 66 141.2 ± 2.7 1.000 140.9 ± 3.0 .927 141.3 ± 3.2 1.000
Serum potassium (mmol/L) 80 4.0 ± 0.6 <.001 4.4 ± 0.6 1.000 4.4 ± 0.5 <.001
Serum creatinine (μmol/L) 78 84.6 ± 20.8 <.001 90.8 ± 24.7 .355 93.6 ± 26.2 <.001
PA
Serum sodium (mmol/L) 17 142.9 ± 2.1 .015 141.0 ± 3.4 .103 142.7 ± 3.4 1.000
Serum potassium (mmol/L) 19 3.4 ± 0.5 <.001 4.3 ± 0.5 1.000 4.3 ± 0.5 <.001
Serum creatinine (μmol/L) 18 85.7 ± 14.1 .011 96.1 ± 22.6 1.000 95.7 ± 19.6 .169
3.3. Main Eﬀects of ARA Treatment. The BP levels at first
followup and at the end of followup are shown in Figure 1.
In EH patients, BP decreased by 13 ± 1.8mmHg systolically
and 6.2 ± 1.0mmHg diastolically at first followup, and by
21 ± 2.1 and 9.7 ± 1.4mmHg at the end of followup. In PA
patients, SBP had decreased by 23 ± 4.8mmHg and DBP
by 9.6 ± 2.5mmHg at first followup and by 28 ± 4.9 and
9.7± 3.1mmHg at the end of followup. Changes in BP were
not significantly diﬀerent for EH and PA patients at both
time points, although a trend existed towards a larger SBP
decrease at first followup in the PA group (P = .063).
Serum potassium and creatinine levels increased signif-
icantly after start of ARA treatment for both EH and PA
patients. Furthermore, in PA patients, serum sodium was
significantly lower at first followup compared to baseline
(Table 2).
At baseline, PA and EH patients used a median num-
ber of 3 antihypertensive drugs (range 2–6). At the end of
followup, the number of drugs had increased to 4 (range 1
to 7, P<.001). However, when expressed in DDD, the total
amount of antihypertensive drugs remained unchanged (5
DDD at baseline versus 4.5 at end of followup, P = .459).
Also in the EH subgroup, the number of antihypertensive
drugs increased from 3 to 4 (P < .001), with a nonsignificant
decrease in DDD (5 DDD at baseline against 4.6 at end of
followup, P = .663). In PA patients, there was no significant
change in number of antihypertensive drugs (3 versus 3,
P = .317) or DDD (3.66 versus 3.83, P = .407).
3.4. Stratification to Followup Duration. Because of the wide
variation in followup duration and to better assess the
long-term eﬃcacy of ARA treatment, patients were strati-
fied according to their treatment followup. The following
categories were formed: 0-1 year, 1–5 years, and >5 years.
Number of patients in these categories were 33, 49, and
International Journal of Hypertension 5
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Figure 2: Changes in systolic (SBP) and diastolic (DBP) blood pressure at the end of followup compared to baseline for three categories of
followup duration (A < 1 year; B 1–5 years; C > 5 years). P values are for trend tested with one-way ANOVA; indicated significance levels are
for diﬀerences between groups after adjustment for multiple comparisons. (EH: essential hypertension; PA: primary aldosteronism).
20, respectively, for EH patients, and 5, 8, and 8 for PA
patients. In Figure 2, blood pressure reduction is shown for
the three categories of followup duration. In EH patients
larger responses were seen with longer followup duration
(P = .001 for ΔSBP and P = .01 for ΔDBP with one-
way ANOVA). In PA patients, a similar trend was seen. The
overall trends were not diﬀerent for EH and PA patients
(P = .467 for ΔSBP and P = .907 for ΔDBP at two-way
ANOVA).
To investigate whether the reduction in BP was merely
a result of a greater number of antihypertensive drugs than
a specific eﬀect of ARA treatment, baseline and end-of-
followup BP is shown in relation to medication use for
EH (Figure 3) and PA (Figure 4). The proportion of total
DDD that consisted of ARA treatment is separately indicated.
These figures show that at longer followup, BP further
decreased, while the total DDD remained unchanged. In
EH patients, the percentage of total DDD consisting of
an ARA significantly increased from 9.1% to 14.2% (P <
.001) in the 1–5-year followup group. In PA patients, the
relative contribution of ARA to total DDD increased from
14.9% to 22.4% in the 1–5-year followup group (P = .050)
and from 14.9% to 31.9% in the >5 years followup group
(P = .018).
3.5. Predictors for the Blood Pressure Response. The main
clinical parameters were tested for their potential association
with SBP as well as DBP response at first and last followup
by univariate regression analysis (with the change in BP
being negative). Table 3 shows the beta coeﬃcients of all
parameters that were significantly associated with BP change
in any of the four groups, as well as those considered
relevant based on earlier reports. At first followup, the
sodium/potassium ratio as well as followup duration were
significantly associated withΔSBP. The ARRwas significantly
associated with ΔDBP, yet with a very small and probably
irrelevant regression coeﬃcient considering the range in
ARR. Interestingly, haemoglobin and hematocrit levels, total
cholesterol, and LDL levels were negatively associated with
blood pressure change at univariate analysis for ΔSBP, and
the latter two also for ΔDBP.
At last followup, the change in BP was significantly
correlated with baseline BP, urinary albumin-to-creatinine
ratio (ACR), LVH, followup duration, and, for DBP, the ARR.
To identify independent predictors for BP response, the
variables significantly associated in the univariate analyses
were included in a multivariate linear regression analysis.
In addition, the model was adjusted for age and sex. The
regression coeﬃcients and significance levels are shown
in Table 4. Unfortunately, hemoglobin, hematocrit, total
cholesterol, LDL, LVH, and the ARR could not be included
in the analysis because numbers were too small to maintain
suﬃcient statistical power.
At first followup, only baseline SBP seemed to be an
independent predictor (borderline significant) for ΔSBP.
For ΔDBP, there were no independent predictors for the
response. At the end of followup, higher baseline BP and
longer FU duration were independently associated with the
change in BP.
3.6. Adverse Events. ARA treatment was in general well
tolerated. In total, 13 adverse events were reported. Five
cases of gynaecomastia were reported with spironolactone
use resulting in a switch to eplerenone in 1 patient. Two
cases of hyperkalemia were seen, and in two patients, a
clinically relevant decrease in renal function was observed.
Two patients (one on eplerenone and one on spironolactone)
reported general discomfort and headache, and one patient
experienced gastrointestinal discomfort, although this was
probably already present before start of spironolactone. In
1 patient, the nature of the adverse event was not further
specified.
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Figure 3: Systolic (SBP) (a), diastolic (DBP) (b) blood pressure and medication use (defined daily dose, DDD) (c) at baseline and end of
followup after stratification for followup duration for patients with essential hypertension (Figure 3) and primary aldosteronism (Figure 4).
Indicated in (c) is the DDD for the aldosterone-receptor antagonist (ARA). For baseline, this is added up to total DDD; at the end of followup,
this is part of the total DDD since ARA was started at baseline. Diﬀerences were tested with paired t-test for SBP and DBP and Wilcoxon
Signed Ranks test for DDD (DDD without ARA at baseline versus DDD including ARA at the end of followup).
4. Discussion
This study shows that the addition of aldosterone-receptor
antagonists (ARAs) in patients with diﬃcult-to-treat hyper-
tension was highly eﬀective in reducing SBP as well as
DBP. This eﬀect was already present at short-term followup
(median followup 8 weeks) and persisted in the long runwith
a median followup of 25 months. The BP reduction in EH
and PA patients was comparable, and in both groups ARA
treatment resulted in a small rise in serum potassium and
creatinine levels.
To assess whether the BP-lowering eﬀect was still present
after prolonged treatment, patients were stratified according
to their duration of followup. We observed larger BP reduc-
tions with increasing followup, which was highly significant
in EH patients. In the subgroup that had a followup of more
than 5 years, SBP was 29mmHg and DBP 16mmHg lower
than at baseline. In PA, a similar trend was seen although
this failed to reach statistical significance, probably because
of the small number of patients in each subgroup. Also in
the multivariate regression analysis we observed a strong
correlation between treatment duration and decrease in BP.
Although it is appealing to conclude that a longer treatment
duration leads to better BP control for instance by reversing
target organ damage, a more likely explanation is some form
of eﬀect-bias implicating that patients with a better response
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Figure 4: Systolic (SBP) (a), diastolic (DBP) (b) blood pressure and medication use (defined daily dose, DDD) (c) at baseline and end of
followup after stratification for followup duration for patients with essential hypertension (Figure 3) and primary aldosteronism (Figure 4).
Indicated in (c) is the DDD for the aldosterone-receptor antagonist (ARA). For baseline, this is added up to total DDD; at the end of followup,
this is part of the total DDD since ARA was started at baseline. Diﬀerences were tested with paired t-test for SBP and DBP and Wilcoxon
Signed Ranks test for DDD (DDD without ARA at baseline versus DDD including ARA at the end of followup).
are more likely to receive ARA treatment for a longer period.
Whether prolonged treatment leads to a better BP control
requires a long-term prospective study.
Another explanation for the favourable long-term BP
response could be an optimalisation of the antihypertensive
medication or merely the fact that the total amount of
medication increased over time. To investigate this further,
BP values at baseline and at end of followup were shown
in relation to total medication use. Although BP decreased
considerably over the study period, the total amount of
DDD remained virtually the same. The relative contribution
of ARA treatment to total DDD increased over time. The
possibility that the improved BP reduction during long-
term followup is due to an increase in total amount of
antihypertensive medication can therefore be excluded.
The BP responses in this study were of similar magnitude
as those observed in other retrospective or open-label studies
concerning add-on ARA treatment [17–21, 23]. Interestingly,
in two prospective trials, BP reductions were considerably
smaller than in the aforementioned studies. Saha et al. [24]
studied the eﬀect of spironolactone in black hypertensive
patients with uncontrolled BP despite the use of at least
a diuretic and a calcium-channel-blocker in a randomized,
placebo-controlled manner and reported a reduction of
7.3mmHg in SBP and 3.3mmHg in DBP. In a recent
study, De Souza et al. [22] assessed the eﬀect of open-label
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spironolactone treatment in resistant hypertension with 24-
hour ambulatory BP measurements, thereby eliminating a
white-coat eﬀect and at least in part also a placebo eﬀect.
In their study, SBP was reduced by 16mmHg and DBP by
9mmHg.
The longest followup in all mentioned studies was 15
months. Whether the eﬀect persists over a longer period
had not yet been reported. With all the limitations of a
retrospective design, our study is the first to show that the
BP lowering eﬀect of add-on ARA treatment is profound and
persistent even after years of treatment.
Earlier publications have focused on identifying clinical
and biochemical predictors for the BP response to ARA
treatment. Several studies have shown that neither plasma
renin concentration or activity, nor aldosterone or the ARR
are good predictors for this response [5, 9, 17, 22, 26],
although this may only hold for patients on multidrug
regimens [25] related to the interfering eﬀects of many
antihypertensives on renin and aldosterone levels [28]. Low
serum potassium levels have consistently been shown to be
associated with a better response [19, 21, 22, 25]. Other
factors potentially related to a better BP response are higher
waist circumference, lower aortic pulse wave velocity [22],
the absence of DM [23], and a lower baseline HDL choles-
terol [21]. In a univariate linear regression analysis, we could
not confirm the predictive value of the serum potassium
level for BP response. However, the sodium/potassium ratio
(as a potential indicator for aldosterone excess) showed a
significant correlation with SBP decrease at short followup
at univariate analysis. In a multivariate analysis, only higher
baseline BP and longer followup duration independently
predicted BP response in the long run. Potential explanations
for this have been discussed earlier in this section. In our
univariate analysis, also haemoglobin, total cholesterol, and
LDL for short-term followup and left ventricular hypertro-
phy and urinary albumin-to-creatinine ratio for long-term
followup were identified as potential predictors. Unfortu-
nately, because of too many missing values, these variables
were not included in the multivariate analysis to maintain
enough statistical power. However, these parameters are
important candidates for further studies on determinants of
BP lowering by ARAs. Plasma renin and aldosterone levels
were not associated with BP response, as has been reported
earlier. In our univariate analysis, the ARR was weakly, yet
significantly, associated with change in DBP. Considering the
median ARR of 9.5 pmol/mU in this patient group, a beta
coeﬃcient of 0.027 is probably of little relevance. Also the
number of patients with ARR available at baseline was too
small to include in the multivariate analysis.
The mechanism that underlies the BP-lowering eﬀect of
add-on ARA treatment is most likely induction of natriure-
sis and diuresis although extrarenal eﬀects of aldosterone
blockade may also be of importance, such as a reduction
in sympathetic tone and modulation of vascular tone, and
in the long run a reduction in vascular stiﬀness may also
play a role (reviewed in [29]). The clinical relevance of
these extrarenal mechanisms is unknown. A cross-over trial
in patients with low-renin hypertension, an elevated ARR,
and a previous favourable BP response to spironolactone
showed that even in this selected population, high-dose
thiazide diuretic treatment was as eﬀective as 100mg of
spironolactone, strongly suggesting that natriuresis is the
most important mode of action [30]. This also underscores
the relevance of dietary salt reduction in resistant hyper-
tension as has been shown elsewhere [31]. In general, ARA
treatment was well tolerated and side eﬀects were rare.
In 13 patients, side eﬀects were reported (10.6%), most
of them presenting with gynaecomastia or hyperkalemia.
The occurrence of sex hormone-related side eﬀects with
spironolactone is dose dependent [32], and in many cases,
these side eﬀects can be prevented by using lower doses.
When this is also not tolerated, treatment with eplerenone,
being a more specific ARA with virtually no sex hormone-
related actions in therapeutic doses, can be considered.
Risk factors for hyperkalemia are advanced age, diabetes
mellitus, higher baseline potassium levels [33], and advanced
stage 3 nephropathy [34]. The presence of renal function
impairment and concomitant use of other diuretics predis-
poses to the development of renal failure [33]. Frequent
monitoring of serum potassium and renal function is
warranted in these patients.
Our study has several limitations, the most significant
one being its retrospective nature. Because of this, there
is an important heterogeneity in patients, treatment, and
followup. To properly assess the long-term eﬃcacy of
ARA treatment taking into account the large diﬀerences in
followup, stratification to followup duration was made. This
makes the analysis prone to bias with overrepresentation of
patients with a good response in the group of prolonged
followup. It would have been more ideal to collect patient
data at several time points during the followup period,
but clinical information in the written files was not always
present. Furthermore, biochemical parameters, especially
haemoglobin and cholesterol (including HDL and LDL)
at baseline, were only available for a limited number of
patients, thereby limiting their usefulness for multivariate
analysis because of lack of statistical power. Also renin and
aldosterone levels were only available for a subset of patients.
This study shows that long-term treatment including an
ARA leads to a persistent BP reduction. Whether this is
attributable to the ARA itself or to better treatment in general
is an important point of consideration. As shown, BP reduc-
tion was not accompanied by an increase in total amount
of antihypertensive drugs, thereby making a specific eﬀect of
the intervention with an ARA more likely. Last, the distinc-
tion between patients with EH and PA was solely based on a
clinical diagnosis by the patient’s physician. A formal confir-
mation test for PA was only performed in a proportion of the
patients labelled with the diagnosis PA. The recent guidelines
for the diagnosis and treatment of PAmade by the Endocrine
Society advise to perform a confirmation test in patients with
an ARR of approximately 91 pmol/mU [35]. From the ranges
in ARR reported in Table 1, it could be deduced that some
of the EH patients actually had PA and that some of the PA
patients had been misdiagnosed. However, considering the
substantial diﬀerences in renin, aldosterone, and potassium
levels between our EH and PA patients, we think that the
diagnosis was correct in most of the patients.
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With all limitations, our results are in favour of a pro-
found and long-term BP lowering eﬀect of ARA treatment
in diﬃcult-to-treat hypertension. To assess the magnitude
of the response more accurately, a randomized, placebo-
controlled trial is needed. With all evidence available, ARAs
at moderate dosages are a welcome treatment option in
patients with diﬃcult-to-treat or resistant hypertension.
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